NCT03295240 2025-05-13The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell LymphomaMemorial Sloan Kettering Cancer CenterPhase EARLY_PHASE1 Completed10 enrolled